List of Excipients in Branded Drug NORPRAMIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Validus Pharmaceuticals LLC	NORPRAMIN	desipramine hydrochloride	30698-007	ACACIA
Validus Pharmaceuticals LLC	NORPRAMIN	desipramine hydrochloride	30698-007	CALCIUM CARBONATE
Validus Pharmaceuticals LLC	NORPRAMIN	desipramine hydrochloride	30698-007	D&C RED NO. 30

Norpramin Excipient Strategy and Commercial Opportunities for Desipramine Hydrochloride

Last updated: August 2, 2026

Norpramin is the former brand name for desipramine hydrochloride, an oral tricyclic antidepressant. Its active-ingredient and primary product patents are long expired, leaving excipients, dosage-form engineering, supply reliability, and regulatory execution as the main commercial levers. The strongest opportunities are a differentiated oral liquid, a patient-friendly tablet, and a low-cost generic platform with robust content uniformity across low strengths.

What drug is Norpramin and how is it formulated?

Norpramin contains desipramine hydrochloride, a secondary-amine tricyclic antidepressant. The historical product was supplied as immediate-release tablets in multiple strengths, including 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, and 150 mg presentations.[1]

The tablet formulation uses conventional pharmaceutical excipients. Public labeling identifies excipient classes including:

Excipient class	Likely function
Dibasic calcium phosphate	Diluent and tablet-strength contributor
Corn starch	Diluent, disintegrant, and processing aid
Gelatin	Binder or granulation aid
Magnesium stearate	Lubricant
Stearic acid	Lubricant and hydrophobic processing aid
Talc	Glidant or anti-adherent
Colorants	Strength identification and product differentiation

Exact excipient composition can vary by manufacturer, strength, and approved abbreviated new drug application. A generic applicant does not need to replicate every inactive ingredient in the former branded product, but the proposed formulation must meet FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and labeling.[2]

The historical immediate-release tablet is technically straightforward. The more difficult formulation problem is achieving consistent dose delivery at the 10 mg and 25 mg strengths while preserving tablet hardness, rapid disintegration, chemical stability, and acceptable swallowing characteristics.

What excipient strategy is appropriate for generic Norpramin tablets?

A conventional direct-compression or wet-granulation platform is the lowest-risk strategy. The preferred design should use widely accepted excipients with established oral safety records and broad supplier availability.

Recommended immediate-release platform

A practical formulation architecture would include:

1. A soluble or partially soluble diluent for tablet mass.
2. A superdisintegrant or starch-based disintegrant to control tablet breakup.
3. A low-level binder to prevent friability.
4. Magnesium stearate or an alternative lubricant at controlled concentration.
5. A glidant to improve powder flow.
6. A film coat or color system that distinguishes strengths.

Microcrystalline cellulose could replace or supplement dibasic calcium phosphate where improved compactability is required. Lactose is another possible diluent, but it introduces greater relevance for patients with lactose intolerance and can affect moisture sensitivity and Maillard-type stability risks when combined with certain excipients or processing conditions.

Dibasic calcium phosphate has a long history in tablet products and can support robust mechanical strength. Its low solubility can slow dissolution if the formulation is over-lubricated or inadequately disintegrated. A formulation using dibasic calcium phosphate should therefore control particle size, lubricant mixing time, compression force, and disintegration performance.

Low-strength content uniformity

The 10 mg strength creates the greatest manufacturing risk because desipramine represents a small proportion of total tablet weight. Content uniformity can be improved through:

• Geometric dilution of the active ingredient.
• Ordered mixing or controlled dry blending.
• Granulation where segregation risk is high.
• Narrow particle-size distributions.
• Low-shear lubrication after final blending.
• In-process blend and tablet testing.
• A common blend strategy across strengths where dose proportionality is justified.

A common blend may reduce manufacturing complexity, but it can create scale-up and tablet-size problems at higher strengths. A strength-specific formulation can improve optimization but increases inventory, validation, and regulatory workload.

What formulation patents protect Norpramin or desipramine products?

Desipramine hydrochloride is an old small-molecule active ingredient. Core composition-of-matter protection and the original Norpramin exclusivity period expired many years ago. The commercial opportunity is therefore not based on exclusivity for the active ingredient.

Protection category	Commercial status
Desipramine composition of matter	Expired
Historical Norpramin tablet patents	Expired or commercially inactive
Immediate-release generic tablet	Generally open to ANDA competition
Novel liquid formulation	Potentially protectable through formulation or method claims
Modified-release formulation	Potentially protectable, subject to clinical and regulatory value
Abuse-deterrent or taste-masked dosage form	Potentially protectable
Manufacturing process	Potentially protectable as a trade secret or process patent
New indication	Potentially protectable through method-of-use claims, subject to statutory requirements

A new excipient system alone does not automatically create meaningful market exclusivity. A formulation patent must provide a non-obvious technical advantage, such as improved stability, reduced precipitation, controlled release, taste masking, or clinically relevant administration benefits.

When does Norpramin lose exclusivity?

Norpramin has already lost conventional small-molecule market exclusivity. No meaningful U.S. exclusivity period should be expected for a standard desipramine hydrochloride immediate-release tablet.

A new product could obtain limited regulatory exclusivity only if it qualifies under a new FDA pathway. Examples include:

Product strategy	Potential FDA pathway	Possible exclusivity concept
Same active, same dosage form	505(j) ANDA	No new clinical exclusivity
New liquid or other formulation	505(b)(2) NDA	Potential 3-year exclusivity for qualifying new clinical investigations
New indication	505(b)(2) NDA or supplemental NDA	Potential 3-year indication-related exclusivity
Pediatric investigation	Pediatric exclusivity	Six months if statutory requirements are met
Orphan indication	Orphan-drug pathway	Seven years if the indication qualifies

A 505(b)(2) product cannot rely on a novel excipient merely as a commercial label. FDA may require formulation development, stability, bioavailability, food-effect, or clinical bridging data depending on the dosage form and proposed claims.[3]

What FDA regulatory pathway applies to a new Norpramin product?

Standard generic tablet

A conventional immediate-release tablet would normally proceed through an ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must establish pharmaceutical equivalence and bioequivalence to the reference listed drug, comply with current good manufacturing practice requirements, and address inactive-ingredient acceptability.[2]

The principal development objectives are:

• Matching the reference product’s dosage form and route.
• Demonstrating equivalent strength.
• Meeting dissolution specifications.
• Showing acceptable bioequivalence.
• Supporting all proposed inactive ingredients at the intended route and maximum daily exposure.
• Establishing stability through the proposed shelf life.

Novel liquid or orally disintegrating product

A liquid, orally disintegrating tablet, chewable tablet, or modified-release product may require a 505(b)(2) application unless the dosage form can be approved through an applicable ANDA pathway.

The regulatory burden increases when the formulation changes:

• Absorption rate.
• Exposure profile.
• Food effect.
• Dosing flexibility.
• Preservative exposure.
• Alcohol compatibility.
• Administration to pediatric or geriatric patients.

A 505(b)(2) program can still use published literature and the known safety profile of desipramine, but it may require bridging studies that a conventional ANDA would avoid.

What commercial opportunities exist for Norpramin excipient innovation?

1. Oral liquid for patients unable to swallow tablets

An oral solution or suspension would address patients with dysphagia, psychiatric-care adherence problems, and dose-titration needs. The product would need to manage:

• Desipramine hydrochloride solubility.
• pH-dependent stability.
• Preservative compatibility.
• Palatability and bitterness.
• Dose-measurement accuracy.
• Container-closure adsorption.
• Light and temperature stability.

A true solution is preferable when feasible because it reduces sedimentation and dose-uniformity risk. If solubility is inadequate, a suspension can use a structured vehicle, wetting agent, suspending polymer, and controlled particle-size distribution.

Potential excipient systems include aqueous buffers, polyols, suspending polymers, sweeteners, flavors, and preservatives. The formulation must avoid excessive viscosity that impairs dosing through oral syringes.

2. Taste-masked pediatric or geriatric product

Desipramine is pharmacologically active at low doses, but bitterness can limit acceptance of a liquid or orally disintegrating dosage form. Taste masking can use:

• Ion-exchange resins.
• Polymer coating.
• Lipid-based barriers.
• Complexation.
• Flavors and sweeteners.
• Multiparticulate encapsulation.

Taste masking creates a stronger formulation story than simply replacing one tablet diluent with another. It can support a 505(b)(2) product if the dosage form delivers a clear administration benefit.

3. Orally disintegrating tablet

An orally disintegrating tablet could improve administration for patients who cannot swallow conventional tablets. A suitable platform would use a highly porous matrix, efficient superdisintegrant, low lubricant load, and flavor system.

The main technical risks are:

• Tablet friability.
• Moisture sensitivity.
• Inadequate dose uniformity at low strengths.
• Slow dissolution caused by hydrophobic excipients.
• Bitter taste after rapid oral dispersion.
• Packaging costs associated with moisture protection.

A blister package may be necessary, reducing the cost advantage versus a conventional bottle.

4. Scored, divisible tablet platform

A modern scored tablet could improve dose titration without introducing modified release. This is commercially relevant because desipramine dosing may require gradual adjustment based on tolerability and response.

The formulation must demonstrate acceptable dose uniformity after tablet splitting if the label promotes division. Tablet geometry, score depth, hardness, friability, and break-force performance become important development parameters.

5. Modified-release product

A sustained-release desipramine product could reduce dosing frequency and smooth peak exposure. It also carries greater development risk because tricyclic antidepressants have clinically important toxicity concerns, and altered pharmacokinetics could affect safety.

A modified-release system could use:

• Hydrophilic matrix polymers.
• Insoluble polymer matrices.
• Coated multiparticulates.
• Osmotic delivery.
• Ion-exchange resin complexes.

The opportunity is commercially narrower than an oral liquid or standard generic because clinical bridging and pharmacokinetic characterization are more demanding. A modified-release formulation would need a clear benefit over inexpensive immediate-release tablets.

How strong is the patent estate for desipramine excipients and formulations?

The underlying desipramine patent estate is weak from a market-exclusivity perspective because the molecule and historical tablet product are old. The stronger IP opportunities relate to a new delivery system rather than ordinary excipient substitution.

Patentable technical themes

Potentially defensible claims could cover:

• A stable desipramine oral solution within a defined pH range.
• A specific taste-masking complex.
• A low-dose tablet with improved content uniformity.
• A modified-release profile linked to a defined polymer system.
• A moisture-protective packaging and formulation combination.
• A manufacturing process that reduces blend segregation.
• A pediatric dosage form with improved dose-measurement accuracy.

Broad claims covering desipramine plus common excipients would face significant prior-art and obviousness challenges. A stronger filing would include comparative data showing improved stability, dissolution, palatability, manufacturability, or pharmacokinetics.

What is the Orange Book status of Norpramin?

The Orange Book identifies FDA-approved drug products, reference listed drugs, patents, and certain exclusivity information.[4] Norpramin’s historical immediate-release tablet protection should not be treated as an active barrier to generic development.

For a current commercial program, the relevant regulatory questions are:

Question	Impact
Is a current reference listed drug available?	Determines the ANDA reference strategy
Is the branded Norpramin product marketed?	Affects substitution and commercial positioning
Are active patents listed?	Determines Paragraph IV and certification strategy
Are exclusivity periods active?	Can delay ANDA approval
Are multiple strengths approved?	Determines launch breadth
Does the proposed product differ in dosage form?	May require 505(b)(2) development

An ANDA applicant challenging any listed patent would use the applicable certification under Hatch-Waxman, including Paragraph IV where appropriate.[5] Given the age of desipramine, the greater risk is often reference-product availability and market size rather than a live blocking patent.

Which companies are challenging Norpramin exclusivity?

Norpramin is not a current high-value branded product with a concentrated patent challenge comparable to recently launched specialty drugs. Generic competition is likely to involve multiple manufacturers or suppliers rather than a single visible Paragraph IV campaign.

Commercial competition may come from:

• Established generic antidepressant manufacturers.
• Contract development and manufacturing organizations.
• Specialty companies focused on oral liquids.
• Compounding pharmacies, where legally permitted.
• Developers of alternative tricyclic or non-tricyclic antidepressants.

The absence of a major patent dispute does not eliminate execution risk. Low-volume products can be vulnerable to discontinuation, supplier concentration, and inadequate manufacturing economics.

What generic launch risks exist for Norpramin?

The principal launch risks are commercial and operational.

Market size and price erosion

Desipramine is a mature antidepressant with substantial therapeutic substitution from selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and other agents. A standard tablet launch may face low reimbursement and rapid price erosion.

Supply continuity

A manufacturer may need to qualify more than one source for:

• Desipramine hydrochloride active ingredient.
• Dibasic calcium phosphate or alternative diluents.
• Colorants.
• Packaging components.
• Oral-liquid preservatives and flavor systems.

Safety-driven prescribing constraints

Desipramine has class-related risks including anticholinergic effects, cardiovascular effects, overdose toxicity, and the antidepressant boxed warning regarding suicidal thoughts and behaviors in younger patients.[1] These risks may limit expansion into pediatric or broad primary-care markets even when a patient-friendly dosage form is available.

Formulation substitution

A low-cost generic tablet can be displaced by another manufacturer unless it has reliable supply, broad strength coverage, and favorable wholesaler economics. Excipients should therefore be selected for cost stability and multi-source availability, not only laboratory performance.

How does Norpramin compare with competing antidepressant opportunities?

Attribute	Desipramine/Norpramin	Modern SSRI generic	Novel antidepressant formulation
Active-ingredient patent position	Expired	Usually expired	May be active
Standard tablet development	Low technical risk	Low technical risk	Variable
Clinical demand growth	Limited	Larger installed base	Depends on indication
Excipient differentiation	Moderate	Usually limited	Potentially high
505(b)(2) opportunity	Possible	Possible but often crowded	More common
Safety-related commercial constraint	High	Generally lower	Product-specific
Price pressure	High	High	Potentially lower with differentiation
Need for patient-friendly dosage form	Meaningful	Often meaningful	Often central

Desipramine is more attractive as a focused formulation or supply-continuity product than as a broad branded-generic tablet. The strongest business case requires a defined underserved population, such as patients requiring liquid dosing or flexible low-dose titration.

What licensing deals could support a Norpramin formulation?

A formulation company could pursue licensing or partnering with:

• A generic manufacturer with an established ANDA platform.
• A specialty pharmaceutical company with 505(b)(2) capabilities.
• A liquid-dose or pediatric formulation specialist.
• A regional distributor with psychiatric-product access.
• A contract manufacturer with low-volume oral-liquid capacity.

A licensing package would be more valuable if it includes formulation know-how, analytical methods, stability data, manufacturing process controls, and regulatory documentation. The active ingredient itself offers limited differentiation because desipramine is widely known and off patent.

What geographic markets are most attractive?

The United States offers the clearest regulatory framework through the ANDA and 505(b)(2) pathways, but commercial value may be constrained by mature generic pricing. European markets may support products for dysphagia and dose titration, although national reimbursement and authorization requirements differ.

Emerging markets may offer demand for low-cost immediate-release tablets but often have stronger price pressure and variable enforcement of formulation IP. A liquid product may have more commercial value where tablet swallowing and dose flexibility are significant treatment barriers, provided preservative and packaging costs remain controlled.

Key Takeaways

• Norpramin is desipramine hydrochloride, an old generic small-molecule antidepressant.
• Core patent and exclusivity barriers have expired.
• A standard immediate-release tablet is technically low risk but commercially vulnerable to price erosion.
• Low-strength content uniformity is the main tablet-development issue.
• The most attractive excipient opportunities are oral liquid, taste-masked, orally disintegrating, and divisible tablet products.
• A novel liquid or modified-release dosage form may require a 505(b)(2) application.
• Formulation patents need comparative evidence, not merely a list of common excipients.
• The best commercial strategy is a differentiated dosage form paired with reliable supply and targeted patient access.
• Paragraph IV litigation risk is likely less important than reference-product availability, market size, and manufacturing economics.
• Desipramine’s safety profile limits the scale of pediatric and broad consumer-oriented opportunities.

FAQs About Norpramin Excipients and Commercial Development

Can a company sell a desipramine tablet with different excipients?

Yes. An ANDA applicant can use different inactive ingredients if the product satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety, and labeling.

Is an oral solution of desipramine likely to receive patent protection?

Potentially. Protection would depend on a technically specific formulation with demonstrated advantages such as improved stability, taste masking, dose uniformity, or delivery performance.

Would a desipramine liquid require new clinical trials?

A liquid product may require a 505(b)(2) application and bridging studies. The scope of clinical work would depend on formulation differences, pharmacokinetics, dosing, and the proposed labeling.

Is Norpramin suitable for a sustained-release formulation?

It is technically feasible, but the commercial case depends on demonstrating a meaningful dosing or tolerability benefit without creating unacceptable pharmacokinetic or safety risks.

Are desipramine excipients a major source of product liability risk?

Inactive ingredients can create risk through allergy, intolerance, contamination, dose nonuniformity, or stability failure. The higher product-specific concern is usually the known pharmacologic toxicity of desipramine and the quality of dose delivery.

References

1. U.S. Food and Drug Administration. (n.d.). Norpramin (desipramine hydrochloride) prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (2019). Applications covered by Section 505(b)(2).
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.